Establishment of personalized antiemetic treatment based on genetic polymorphisms

点击翻译按钮获取中文摘要

Chemotherapy-induced nausea and vomiting (CINV) are one of the most unpleasant non-haematological adverse effects that affect the well-being of cancer patients. The aim of this study was to evaluate the association between the antiemetic efficacy and the ABC polymorphisms and clarify the risk of CINV. Patients receiving highly emetogenic chemotherapy were examined for antiemetic responses to aprepitant in combination with granisetron and dexamethasone. The multivariate logistic regression analyses showed that female gender, age <50 years, ABCB1 1236 TT , and ABCG2 421 AA were associated with antiemetic treatment failure in the acute phase. In contrast, only female gender was associated in the delayed phase.